272 filings
DEFA14A
NGNE
Neurogene Inc
26 Apr 24
Additional proxy soliciting materials
2:34pm
ARS
2023 FY
NGNE
Neurogene Inc
26 Apr 24
Annual report to shareholders
2:33pm
DEF 14A
NGNE
Neurogene Inc
Definitive proxy
26 Apr 24
2:33pm
8-K
NGNE
Neurogene Inc
24 Apr 24
Departure of Directors or Certain Officers
5:47pm
8-K
NGNE
Neurogene Inc
22 Apr 24
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
4:44pm
8-K
3cc56qff3s xv9
2 Apr 24
Departure of Directors or Certain Officers
3:43pm
8-K
giq0j yzv4n8f6ljm
18 Mar 24
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
4:10pm
8-K
i408q4
4 Mar 24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
7:30am
8-K
s2iunw
21 Feb 24
Departure of Directors or Certain Officers
4:07pm
S-8
llmuw34rrl6 9rlky
20 Feb 24
Registration of securities for employees
4:16pm
8-K
togop4sw1xm lm
5 Jan 24
Neurogene Announces Business Update and 2024 Outlook
7:11am
8-K
qql4ea
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
425
gp92s0 rvw
6 Dec 23
Business combination disclosure
4:24pm
8-K
swz2m50t9imtvnusbzz
6 Dec 23
Other Events
4:21pm
425
vls i3l4lz
4 Dec 23
Business combination disclosure
5:14pm
8-K
9uf 4kdaw2tm3npq
4 Dec 23
Other Events
5:10pm
425
51y9w1
30 Nov 23
Business combination disclosure
4:06pm
EFFECT
5e2x2g2jgg
14 Nov 23
Notice of effectiveness
12:15am